Rifapentine pharmacokinetics in adolescents

Pediatric Infectious Disease Journal

Volumn 18, Issue 10, 1999, Pages 882-888

  Marshall, James D ^a,b,c   Abdel Rahman, Susan ^a,b,c   Johnson, Kathy ^c   Kauffman, Ralph E ^a,b,c   Kearns, Gregory L ^a,b,c  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^c CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

Pediatric; Pharmacokinetics; Rifapentine; Tuberculosis

Indexed keywords

RIFAPENTINE;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RIFAMPIN;

EID: 0032847714     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199910000-00009     Document Type: Article

References (27)

1. Josefson D. FDA approves tuberculosis drug [News]. BMJ 1998;317:11.
2. Dickinson JM, Mitchison DA. In vitro activity of selected rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. Tubercle 1987;68:177-82.
3. Werli W, Knusel F, Schmid K, et al. Interaction of rifamycin with bacterial RNA polymerase. Proc Natl Acad Sci USA 1968;61:667-73.
4. Keung A, McKenzie K, Worth J. Pharmacokinetics and dose proportionality study of rifapentine in healthy male volunteers. Hoechst Marion Roussel, Project Report No. K-96-0465-D, 1996.
5. Keung A, Eller M, Weir S. Single-dose pharmacokinetics of rifapentine in women. J Pharmacokinet Biopharm 1998;26: 75-85.
6. Keung A, Eller M, Weir S. Single-dose pharmacokinetics of rifapentine in elderly men. Pharm Res 1998;15:1286-91.
7. 14C-rifapentine in healthy volunteers. Drug Metab Dispos 1998;26:732-8.
8. Leeder J. Developmental aspects of drug metabolism in children. Drug Inf J 1996;30:1135-43.
9. Reed M. The ontogeny of drug disposition: focus on drug absorption, distribution, and excretion. Drug Inf J 1996;30: 1129-34.
10. Hoescht Marion Roussel. Project Report No. K-96-0919-D, 1996.
11. Mor N, Simon B, Mezo N, Heifets L. Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages. Antimicrob Agent Chemother 1995;39:2073-7.
12. Leinweber F. Possible physiologic roles of carboxylic ester hydrolases. Drug Metab Rev 1987;18:379-439.
13. Emary B, Toren P, Mathews B, Huh K. Disposition and metabolism of rifapentine, a rifamycin antibiotic, in mice, rats, and monkeys. Drug Metab Dispos 1998;26:725-31.
14. Nakagawa H, Sunahara S. Glucuronidation and desacetylation in the metabolism of rifampicin in man. Presented at the Twenty-third International Tuberculosis Conference, Mexico City, 1975.
15. Gidoh M, Sakamoto Y, Tsutsumi S, Nakagawa H. Fundamental studies on the metabolism of rifampicin (RFP). Nippon Rai Gakkai Zasshi 1978;47:110-22.
16. Iatsimirskaia E, Tulebaev S, Storozhuk E. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997;61:554-62.
17. Nebert D. Polymorphisms in drug-metabolizing enzymes: what is their clinical relevance and why do they exist? Am J Hum Genet 1997;60:265-71.
18. Romeo B, Pugnetti P, Bernareggi A, et al. Pharmacokinetics and tolerability of increasing single oral doses of rifapentine (600, 900 and 1200 mg) after a standard meal, and of the dose of 600 mg after a standard breakfast in healthy volunteers [Abstract). Presented at the Ninth International Symposium of Future Trends in Chemotherapy, Geneva, March 26 to 28, 1990.
19. Keung A, Miller T, Green V, Ames M, Eller M, Weir S. Bioavailability and food effect study of rifapentine in healthy adults [Abstract]. Pharm Res 1995;12(Suppl):S419.
20. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47-65.
21. Skinner M, Blaschke T. Clinical pharmacokinetics of rifabutin. Clin Pharmacokinet 1995;28:115-25.
22. Vital-Durand D, Hampden C, Boobis A, Park B, Davies D. Induction of mixed function oxidase activity in man by rifapentine (MDL 473), a long-acting rifamycin derivative. Br J Clin Pharmacol 1986;21:1-7.
23. Keung A, Eller M, Weir S. Pharmacokinetics of rifapentine in patients with varying degrees of hepatic dysfunction. J Clin Pharmacol 1998;38:517-24.
24. Keung A, Owens R, Eller M, Weir S, Nicolau D, Nightingale C. Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study. Antimicrob Agents Chemother 1999;43:1230-3.
25. Jarvis B, Lamb H. Rifapentine. Drugs 1998;56:607-16.
26. Acocella G. Clinical pharmacokinetics of rifampicin. Clin Pharmacokinet 1978;3:108-27.
27. American Academy of Pediatrics. Tuberculosis. In: Peter G, ed. 1997 Red Book: Report of the Committee on Infectious Diseases. 24th ed. Elk Grove Village, IL: American Academy of Pediatrics, 1997:541-62.